Ascendis Pharma A/S (NASDAQ:ASND) Trading 5.9% Higher – Here’s Why

Ascendis Pharma A/S (NASDAQ:ASND)’s share price traded up 5.9% during trading on Monday . The company traded as high as $136.88 and last traded at $136.82. 266,899 shares were traded during mid-day trading, a decline of 35% from the average session volume of 409,644 shares. The stock had previously closed at $129.19.

Analysts Set New Price Targets

ASND has been the subject of several recent analyst reports. TD Cowen decreased their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective for the company. Wells Fargo & Company increased their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Stifel Nicolaus lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Price Performance

The business has a 50-day moving average of $132.84 and a 200 day moving average of $133.54. The company has a market capitalization of $8.19 billion, a PE ratio of -16.69 and a beta of 0.65.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in ASND. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S in the third quarter valued at $30,000. Groupama Asset Managment purchased a new stake in Ascendis Pharma A/S during the third quarter valued at $60,000. GAMMA Investing LLC lifted its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the last quarter. Signaturefd LLC grew its stake in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.